SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

20 November 2008

 

 

PROTHERICS PLC

(Translation of Registrant’s Name Into English)

 

 

The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F       X              Form 40-F               

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):             

 

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes                     No          X     

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-              .

 

 

The Registrant is furnishing a copy of its announcements as reported to the Company Announcements Office of the London Stock Exchange.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

       

 

PROTHERICS PLC

       

Date: 20 November 2008

 

By:

 

/s/ Rolf Soderstrom

       

Rolf Soderstrom

       

Finance Director



 

 

 

Protherics PLC


Notification of Major Interests in Shares



London, UK; Brentwood, TN, US: 20 November 2008 -  Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 19 November 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA").  Details of the interest notified are set out below.



1.    Reason for the notification   (please tick the appropriate box or boxes)     




An acquisition of voting rights 


X

 

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached




An event changing the breakdown of voting rights




Other (please specify)



2. Full name of person(s) subject to the notification obligation:

AXA S.A., 25 Avenue Matignon, 75008 Paris and its group of companies.

3. Full name of shareholder(s) (if different from 2.):



4. Date of the transaction (and date on which the threshold is crossed or reached if different):

18 November 2008

5. Date on which issuer notified:

19 November 2008

6. Threshold(s) that is/are crossed or reached:

12%


7. Notified details:





A: Voting rights attached to shares

Class/type of shares 

if possible using the ISIN CODE

Situation previous to the Triggering transaction 

Resulting situation after the triggering transaction

Number of Shares 

Number of Voting Rights 

Number of shares 

Number of voting rights 

% of voting rights

Direct

Direct

Indirect 

Direct

Indirect


0702920



42,026,712


42,026,712


1,041,666


1,041,666


41,322,546


0.30%


11.79%




B: Financial Instruments

Resulting situation after the triggering transaction 

Type of financial instrument 

Expiration date 

Exercise/ Conversion Period/ Date  

Number of voting rights that may be acquired if the instrument is exercised/ converted. 

% of voting rights












Total (A+B)

Number of voting rights

                      % of voting rights


42,364,212


                      12.09%




8. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable :

 

Name of Company/Fund


 

Number of Shares

 

% of issued share capital

AXA

Direct

716,666


0.20451   


AXA Framlington

Indirect

41,322,546


11.79204


AXA IM UK

Direct

325,000


0.09274



Total Direct

Total Indirect


1,041,666

41,322,546



0.29726

11.79204



TOTAL


42,364,212



12.08930








Proxy Voting:

9. Name of the proxy holder:

 


10. Number of voting rights proxy holder will cease to hold:

 


11. Date on which proxy holder will cease to hold voting rights:

 





12. Additional information:








| Ends |



For further information please contact:


Protherics 


Nick Staples, Director of Corporate Affairs

+44 (0) 7919 480510  

Julie Vickers, Company Secretary 

+44 (0)1928 518010



Financial Dynamics  - press enquiries


London: Ben Atwell, Lara Mott

+44 (0) 20 7831 3113 

New York: John Capodanno

+1 212 850 5600




Or visit   www.protherics.com

 

 

 

 
Protherics (NASDAQ:PTIL)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Protherics Charts.
Protherics (NASDAQ:PTIL)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Protherics Charts.